|
01 Dec 2020 |
TG Therapeutics Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration for Ublituximab in Combination with Umbralisib as a Treatment for Patients with Chronic Lymphocytic Leukemia
|
|
01 Dec 2020 |
MacroGenics Announces Achievement of $25 Million in Milestones Related to Retifanlimab Collaboration with Incyte
|
|
01 Dec 2020 |
Kiniksa Announces Preliminary Data from Phase 1 Trial of KPL-404
|
|
01 Dec 2020 |
Junshi Biosciences Announces Dosing of First Patient in Phase I Study of Anti-TROP2 Antibody -TUB196 Conjugate
|
|
01 Dec 2020 |
Dupixent® (dupilumab) Approved by European Commission as First and Only Biologic Medicine for Children Aged 6 to 11 Years with Severe Atopic Dermatitis
|
|
01 Dec 2020 |
SAB Biotherapeutics Awarded $57.5M from BARDA and U.S. Department of Defense for Manufacturing of SAB-185 for the Treatment of COVID-19
|
|
01 Dec 2020 |
Zymeworks Receives FDA Breakthrough Therapy Designation for HER2-Targeted Bispecific Antibody Zanidatamab in Patients with Biliary Tract Cancer
|
|
27 Nov 2020 |
AbbVie and Eisai Announce an approval for additional indication of HUMIRA®, a fully Human Anti-TNFα Monoclonal Antibody, for the treatment of pyoderma gangrenosum for the first time in the world
|
|
26 Nov 2020 |
FDA Approves Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma
|
|
26 Nov 2020 |
Celltrion completes enrolment for global Phase II clinical trial with COVID-19 treatment candidate CT-P59
|
|
26 Nov 2020 |
Bio-Thera Solutions Submits Marketing Authorization Application (MAA) for BAT1706, a Proposed Biosimilar to Avastin®, to European Medicines Agency (EMA)
|
|
25 Nov 2020 |
Integral Molecular Announces Best-in-Class Antibodies Against Complex Oncology Target Claudin 18.2
|
|
25 Nov 2020 |
F-star Therapeutics Announces Clearance of Clinical Trial Application for FS222
|
|
25 Nov 2020 |
European Commission Approves Janssen’s TREMFYA (guselkumab), a First-in-Class Treatment for Active Psoriatic Arthritis (PsA)
|
|
25 Nov 2020 |
Genmab Announces Enapotamab Vedotin Update
|
|
24 Nov 2020 |
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Second-Line Treatment for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
|
|
23 Nov 2020 |
Pfizer Doses First Participant in Phase 3 Study Evaluating anti-TFPI Investigational Therapy, Marstacimab, for People With Severe Hemophilia A and B With or Without Inhibitors
|
|
23 Nov 2020 |
Twist Bioscience Announces Positive Preclinical Data for SARS-CoV-2 Antibodies
|
|
23 Nov 2020 |
Immunocore’s tebentafusp demonstrates superior overall survival compared to investigator’s choice in a Phase 3 clinical trial of patients with previously untreated metastatic uveal melanoma
|
|
22 Nov 2020 |
Regeneron's REGEN-COV2 is First Antibody Cocktail for COVID-19 to Receive FDA Emergency Use Authorization
|
|
20 Nov 2020 |
Alvotech Announces That the U.S. FDA and EMA Have Accepted Regulatory Submissions for AVT02, a Proposed Biosimilar to HUMIRA® (adalimumab)
|
|
20 Nov 2020 |
BeiGene Announces the Approval of XGEVA® (Denosumab) in China for the Prevention of Skeletal-Related Events in Patients With Bone Metastases From Solid Tumors and in Patients With Multiple Myeloma
|
|
20 Nov 2020 |
SynOx Therapeutics raises €37M in Series A Financing
|
|
20 Nov 2020 |
Imfinzi approved in the US for less-frequent, fixed-dose use
|
|
20 Nov 2020 |
Alexion Receives Marketing Authorization from European Commission for New Formulation of ULTOMIRIS® (ravulizumab) with Significantly Reduced Infusion Time
|
